ArticleInternational ophthalmology2025
Keratitis after keratoplasty: risk modifiers, microbial resistance and outcomes in the COVID-19 era.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Increased risk of corneal transplant rejection following SARS-CoV-2 infection and vaccination.International ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluated the risk of keratitis following corneal transplantation in Auckland, New Zealand, a mild, humid, subtropical climate, assessing risk factors, causative organisms, and graft outcomes.
methodsAll corneal transplants performed in Auckland from 2010 to 2022 were reviewed. Clinical records provided demographic data, graft type, compliance, follow-up, organisms cultured, antibiotic resistance, and transplant outcomes.
resultsA total of 1184 keratoplasties (974 patients) were performed with mean follow-up of 4.2 years (IQR 1.8-7.9). Cumulative incidence of keratitis was 2.4% at one year and 6.0% at five years. Cases were bacterial (72.6%), viral (12.3%), fungal (5.4%), parasitic (2.7%) and autoimmune (6.8%). On multivariate analysis, Asian ethnicity (HR 8.76, 95% CI 6.2-9.6, p < 0.001), increasing age (HR 1.02, 95% CI 1.01-1.07, p = 0.012) and poor treatment compliance (HR 5.75, 95% CI 4.8-6.9, p < 0.001) were associated with increased risk. Anterior lamellar keratoplasty did not demonstrate increased risk (HR 0.50, 95% CI 0.37-1.04, p = 0.410), while endothelial keratoplasty reduced risk compared with penetrating keratoplasty (HR 0.17, 95% CI 0.02-0.4, p = 0.017). The rate of keratitis among endothelial grafts was 2.1% compared with 7.8% in penetrating keratoplasties. 7.9% of anterior lamellar keratoplasties developed keratitis, but this was not statistically significant (HR 0.50, 95% CI 0.37-1.04, p = 0.410). Keratitis significantly increased risk of graft failure compared with total graft failure rate (OR 2.5, 95% CI 1.8-3.6, p < 0.001). The COVID-19 pandemic period did not affect incidence (HR 1.00, 95% CI 0.9 -1.3, p = 0.104). Antibiotic resistance among bacterial isolates was low: 0% to vancomycin, 3.1% to tobramycin, 9.4% to ciprofloxacin/cephalosporins, and 25% to penicillin.
conclusionDuring a 12 year period with 1184 keratoplasties, the cumulative risk of keratitis increased substantially throughout the post-operative course, to affect 6% of transplants at five years. Fortunately, antibiotic-resistant organisms remain relatively uncommon in NZ. An episode of keratitis significantly increased the risk of corneal graft failure. Grafts performed in the COVID-19 pandemic era did not demonstrate an increased risk of keratitis. Compliance and the type of graft were the only potentially modifiable risk factors.
Indexed as
Identifiers
41222771What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.